SEC Form 4 · accession 0001179110-18-009704
MOMENTA PHARMACEUTICALS INC · MNTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Young Kwon
Officer — SVP, Corporate Development
Period of report
Jul 12, 2018
Accepted (ET)
Jul 16, 2018 · 5:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235010
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 12, 2018 | M | 11,000 | $13.26 | A | 148,623 | D | |
| Common StockF2 | Jul 12, 2018 | S | 11,000 | $25.40 | D | 137,623 | D | |
| Common Stock | Jul 12, 2018 | M | 5,500 | $15.44 | A | 143,123 | D | |
| Common StockF2 | Jul 12, 2018 | S | 5,500 | $25.54 | D | 137,623 | D | |
| Common Stock | Jul 12, 2018 | M | 6,000 | $12.58 | A | 143,623 | D | |
| Common StockF2 | Jul 12, 2018 | S | 6,000 | $25.41 | D | 137,623 | D | |
| Common Stock | Jul 12, 2018 | M | 6,000 | $17.96 | A | 143,623 | D | |
| Common StockF2 | Jul 12, 2018 | S | 6,000 | $25.41 | D | 137,623 | D | |
| Common Stock | Jul 12, 2018 | M | 4,000 | $13.02 | A | 141,623 | D | |
| Common StockF2 | Jul 12, 2018 | S | 4,000 | $25.41 | D | 137,623 | D | |
| Common Stock | Jul 12, 2018 | M | 2,000 | $21.56 | A | 139,623 | D | |
| Common StockF3 | Jul 12, 2018 | S | 2,000 | $25.91 | D | 137,623 | D | |
| Common StockF4 | Jul 12, 2018 | S | 11,999 | $25.40 | D | 125,624 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option(Right to Buy) | $13.26 | Jul 12, 2018 | M | 11,000 | D | Feb 22, 2015 | Feb 22, 2021 | Common Stock | 11,000 | 30,500 | D |
| Stock Option(Right to Buy) | $15.44 | Jul 12, 2018 | M | 5,500 | D | Feb 14, 2016 | Feb 14, 2022 | Common Stock | 5,500 | 16,500 | D |
| Stock Option(Right to Buy) | $12.58 | Jul 12, 2018 | M | 6,000 | D | Feb 19, 2017 | Feb 19, 2023 | Common Stock | 6,000 | 16,800 | D |
| Stock Option(Right to Buy) | $17.96 | Jul 12, 2018 | M | 6,000 | D | Feb 18, 2018 | Feb 18, 2024 | Common Stock | 6,000 | 19,986 | D |
| Stock Option(Right to Buy) | $13.02 | Jul 12, 2018 | M | 4,000 | D | May 18, 2018 | Feb 18, 2025 | Common Stock | 4,000 | 25,725 | D |
| Stock Option(Right to Buy) | $21.56 | Jul 12, 2018 | M | 2,000 | D | May 11, 2018 | Aug 11, 2025 | Common Stock | 2,000 | 18,000 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- F2This transaction was executed in multiple trades at prices ranging from $24.90 to $25.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F3This transaction was executed in multiple trades at prices ranging from $25.90 to $25.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F4This transaction was executed in multiple trades at prices ranging from $24.90 to $25.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.